陈旭伟1 孙伟2△ 崔世义1.uPA、PAI-1 的表达和MVD 计数与浸润性乳腺癌侵袭性的关系[J].现代生物医学进展英文版,2011,11(12):2307-2309. |
uPA、PAI-1 的表达和MVD 计数与浸润性乳腺癌侵袭性的关系 |
Relationship Between Expression of uPA ,PAI-1 and Microvessel Densityand Invasiveness of Primary Invasive Breast Cancer |
|
DOI: |
中文关键词: 尿激酶型纤溶酶原激活因子 尿激酶型纤溶酶原激活物抑制因子 乳腺癌 侵袭性 免疫组化 |
英文关键词: Urokinase plasminogen activator(uPA) Plasminogen activator inhibitor(PAI-1) Breast cancer Invasiveness Immunohistochemistry |
基金项目: |
|
Hits: 678 |
Download times: 1067 |
中文摘要: |
目的:探讨尿激酶型纤溶酶原激活剂(uPA)、纤溶酶原激活物抑制剂(PAI-1)的表达和血管形成与浸润性乳腺癌侵袭性的关
系。方法:应用免疫组化SP 法检测80 例浸润性乳腺癌、20 例良性乳腺肿瘤组织中uPA、PAI-1 的表达情况并进行微血管计数。结
果:uPA 和PAI-1 在浸润性乳腺癌组的阳性表达显著高于良性肿瘤组,且其高表达率与乳腺癌的临床病理参数密切相关(P<0.
05);微血管计数在乳腺癌组和良性肿瘤组分别为30.87±7.64、20.28±8.72,两组比较有显著性差异(P<0.01)。uPA 与PAI-1 在浸
润性乳腺癌中的表达呈正相关(P<0. 05)。结论:uPA、PAI-1 的高表达与浸润性乳腺癌的浸润、转移相关,uPA、PAI-1 的高表达和
MVD 计数可作为评价浸润性乳腺癌侵袭性、评估预后和确定治疗方案的生物学指标。 |
英文摘要: |
Objective: To detect the expression of uPA (urokinase plasminogen activator)、PAI-1 (plasminogen activator inhibitor
type 1) and angiogenesis in breast cancer and their relationship with the invasiveness of breast cancer. Methods: Eighty surgically
resected breast cancer samples and twenty breast benign tumor samples were selected.S-P immunostaining technique was used to detect
the expression of uPA、PAI-1and MVD in all of the tissues. Results: The positive expression rates of uPA、PAI-1 in breast cancer was
significantly higher than that in the breast benign tumors, and their high expression rates were related with the clinical pathology
parameters of the breast cancer (P<0.05). MVD were respectively 30.87±7.64, 20.28±8.72 in breast cancer and breast benign tumor
group. There was significantly difference between the two groups (P<0.01).There were positive correlations between the level of uPA
and PAI-1 in breast cancer (P<0.05). Conclusion: The expression of uPA and PAI-1 correlated with the invasiveness and metastasis of
breast cancer,and they could be used as biological indicators that evaluate the invasiveness and metastasis,estimate prognosis and
determine treatment of primary invasive breast cancer. |
View Full Text
View/Add Comment Download reader |
Close |